Search clinical trials for: Ad26.ENVA.01 vaccine

Total 69 results

National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults

HIV Infections

United States
International AIDS Vaccine Initiative
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

HIV Infections

United States, Kenya, Rwanda, South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; IPPOX Foundation; Center for HIV/AIDS Vaccine Immunology...

Withdrawn

Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults

HIV Infections
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers

Ebola Disease | Marburg Disease

United States
Universiteit Antwerpen
Johnson & Johnson; University of Kinshasa; Innovative Medicines Initiative; Coalition... and other collaborators

Completed

Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola (EBOVAC3DRC)

Ebola Virus Disease

Congo, The Democratic Republic of the
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

HIV Infections

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

Respiratory Syncytial Virus Prevention

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

Respiratory Syncytial Virus Prevention

United States
Crucell Holland BV
The PATH Malaria Vaccine Initiative (MVI); Seattle Children's Research Institute...

Completed

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

Malaria

United States
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III (COVID-19)

COVID-19 Pandemic

Philippines, Indonesia, Russian Federation
Livzon Pharmaceutical Group Inc.

Completed

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study (COVID-19)

COVID-19 Pandemic

Malaysia, Pakistan
Crucell Holland BV

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

Respiratory Syncytial Virus Infection Prevention

Germany, Spain, Belgium, Sweden, United States
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (COVID-19)

COVID-19 Pandemic

China
Barbara Ensoli, MD
Novartis Vaccines

Terminated

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

HIV Infection

Italy
Janssen Pharmaceutical K.K.

Terminated

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

Respiratory Syncytial Virus Prevention

Japan
Hospital Moinhos de Vento
Pfizer; Universidade Federal do Paraná; Inova Medical

Completed

A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil

Covid19

Brazil
University Medical Center Groningen
Radboud University Medical Center; Erasmus Medical Center; Academisch Medisch... and other collaborators

Completed

RECOVAC Repeated Vaccination Study

Kidney Diseases | Covid19 | SARS-CoV2 Infection | Vaccine Response Impaired

Netherlands
University of Oxford

Enrolling by invitation

Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients (CVTB)

Tuberculosis | Covid-19 Pandemics

Thailand
Centre Hospitalier Universitaire de Saint Etienne

Active, not recruiting

Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen (CoviCompare_J)

Healthy Volunteers

France
Mahidol University

Completed

Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais

Healthy

Thailand
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

COVID-19 Prevention

United States, Belgium, Poland
Janssen Vaccines & Prevention B.V.
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Completed

A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

Ebola Virus Disease

Guinea, Sierra Leone
London School of Hygiene and Tropical Medicine
Public Health England; Janssen Vaccines & Prevention B.V.; Epicentre; Coalition... and other collaborators

Active, not recruiting

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Ebola Virus Disease

Congo, The Democratic Republic of the
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults

HIV Infections

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

Ebola

United States
Janssen Vaccines & Prevention B.V.
Bavarian Nordic GmbH

Terminated

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Hemorrhagic Fever, Ebola

France, United Kingdom, Kenya, United States, Uganda, Burkina Faso, Tanzania
Janssen Vaccines & Prevention B.V.

Completed

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

Healthy

United States, Mexico, Spain, Puerto Rico, Italy, Poland, Argentina, Brazil, Peru
Massachusetts General Hospital

Completed

Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
London School of Hygiene and Tropical Medicine
University of Sierra Leone; Janssen Vaccines & Prevention B.V.

Active, not recruiting

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

Infections | RNA Virus Infections | Virus Diseases | Mononegavirales Infections | Hemorrhagic Fevers, Viral | Hemorrhagic Fever, Ebola | Filoviridae Infections | Physiological Effects of Drugs | Vaccines | Ebola | Immunologic Factors

Sierra Leone
AstraZeneca

Completed

Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study (REFORCO-B)

COVID-19

Brazil
Livzon Pharmaceutical Group Inc.

Active, not recruiting

The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine (Omicron)

COVID-19 Pandemic

China
National Institute of Allergy and Infectious Diseases...

Completed

Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso

Malaria

Burkina Faso
National Institute of Allergy and Infectious Diseases...

Completed

Adenovirus Vaccine for Malaria

Plasmodium Falciparum Infection

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
Wits Health Consortium (Pty) Ltd
Fred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; National Institute... and other collaborators

Completed

Sisonke (Together): OPEN LABEL TRIAL COVID-19 (Sisonke)

SARS (Severe Acute Respiratory Syndrome)

South Africa
Boris Juelg, MD PhD
National Institute of Allergy and Infectious Diseases (NIAID); The University... and other collaborators

Recruiting

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases, Viral | Retroviridae Infections | HIV | Immunologic Deficiency Syndrome, Acquired

United States
GlaxoSmithKline
Crucell Holland BV; The PATH Malaria Vaccine Initiative (MVI)

Completed

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

Malaria

United States
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity (COVID-19)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization (COVID-19)

COVID-19 Pandemic

China
Livzon Pharmaceutical Group Inc.
Simoon Record Pharma Information Consulting Co., Ltd.; Guangdong Center for...

Completed

Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

COVID19

China
R-Pharm
AstraZeneca

Completed

Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

COVID-19

United Arab Emirates
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network; IPPOX Foundation; CHAVI; MHRP

Completed

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

HIV Infections

United States, Switzerland
The Aurum Institute NPC
Coalition for Epidemic Preparedness Innovations

Recruiting

Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults. (AUR1-8-341)

COVID-19

South Africa
Washington University School of Medicine
Merck Sharp & Dohme LLC

Withdrawn

Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small Cell Lung Extensive Stage
National Institute of Allergy and Infectious Diseases...
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Active, not recruiting

Partnership for Research on Ebola VACcinations (PREVAC)

Ebola Virus Disease

Guinea, Liberia, Mali, Sierra Leone
University Hospital Inselspital, Berne

Recruiting

Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab. (RituxiVac)

Immunosuppression | Rituximab | COVID19 Vaccination

Switzerland

Search clinical trials for: Ad26.ENVA.01 vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations